SecBot SecBot

INMB

Inmune Bio, Inc.
Nasdaq· Biological Products, (No Diagnostic Substances)· Inc. NV· CIK 0001711754 Biotech & Drug Discovery
$1.44 −0.02 (−1.36%)
Oct 26 4:00 PM ET · prev $1.46
Market cap
$42.7M
Nano cap
Median target
$8.00
+456% · range $4.00–9.00
Next earnings
Nov 4
in 9 days · EPS est. −$0.20
1 year
−21.7%
from $1.84 · Oct 27
30 days
−28.0%
from $2.00
52-week range
$1.12–2.51
−43% from high · low Mar 27
Avg volume 20D
277.7K
Oct 14 spike 1.14M
Short interest
2.66M
≈9.6% of shares · +18.1%
Days to cover
7.0
at average volume
Insider net
$0
no open-market trades · 12 mo
New fund stakes
0
Q2 2026 13F · 0 exits
Filing reports
9
analyzed by SecBot
SecBot read BULLISH 2 reports · 90 days
Balance 0 bearish · 1 bullish · 1 neutral oldest → newest, height = score
Avg score ·High conf. 2/2 ·Next Earnings date, Nov 4, 2026
Strongest BULLISH INmune Bio filed an 8-K announcing two key Ebstrocel (CORDStrom) milestones: submission of a pre-MAA package…
All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

Signal stack

Where each data set points today.

  • InsidersNO TRADES

    No open-market buys or sells in 12 months. Recent filings are awards, exercises and tax withholding.

  • InstitutionsMIXED

    Q2 2026: 12 added (0 new), 13 trimmed or exited.

  • EstimatesFALLING

    Current-quarter EPS estimate −$0.165 → −$0.200 over 90 days. 1 up, 0 down in 30 days.

  • Short sellersBUILDING

    Short interest +18.1% to 2.66M shares. 7.0 days to cover, ≈9.6% of shares.

  • TrendDOWNTREND

    30% below its 50-day average.

Who's buying

13F· Q2 2026
0
new positions
0
exits
FundMoveSharesValue
BlackRock, Inc.TRIM311,613$507.9K
GEODE CAPITAL MANAGEMENT, LLCTRIM190,215$310.3K
JANE STREET GROUP, LLCDOUBLED134,232$218.8K
UBS Group AGTRIM110,413$180.0K
STATE STREET CORPTRIM93,363$152.2K
IEQ CAPITAL, LLCDOUBLED82,385$134.3K
Mariner, LLCDOUBLED40,320$65.7K
NORTHERN TRUST CORPNEAR_EXIT37,670$61.4K

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

last action Mar 2026
12-month targets · 3 analysts

Price is below the lowest target. Median implies +456%.Targets as of Oct 26, 2026.

Recent actions
DateFirmActionRating
Mar 11, 2026LUCID CAPITAL MARKETS
UPGRADE
UPGRADEBuy
Jul 2, 2025Maxim Group
MAINTAIN
MAINTAINBuy
Jul 1, 2025BTIG
DOWNGRADE
DOWNGRADENeutral
Jul 1, 2025Scotiabank
DOWNGRADE
DOWNGRADESector Underperform
Feb 13, 2025Maxim Group
MAINTAIN
MAINTAINBuy
Feb 11, 2025Scotiabank
MAINTAIN
MAINTAINSector Outperform

Insider ledger

Form 4
$0
open-market buys or sells · 12 mo
DateInsiderTypeValue
Sep 15, 2026
SAPIRSTEIN JAMES
Director
AWARD100,000 sh
Sep 15, 2026
Clark Ronnie Duane
Director
AWARD100,000 sh
Jul 2, 2026
Juda Scott
Director
EXERCISE$1.9K
Jul 2, 2026
Juda Scott
Director
EXERCISE$20.7K
Jul 2, 2026
Lowdell Mark William
Chief Scientific Officer
EXERCISE$901.38
Jul 2, 2026
Lowdell Mark William
Chief Scientific Officer
EXERCISE$10.1K
Jul 2, 2026
Moss David J
Chief Executive Officer
EXERCISE$1.1K
Jul 2, 2026
Moss David J
Chief Executive Officer
EXERCISE$12.6K

Earnings setup

Estimates
Nov 4
reports in 9 days
−$0.20
EPS estimate, this quarter
−21%
estimate change, 90 days
1↑ 0↓
revisions, 30 days
Current-quarter EPS estimate
PeriodEPS est.Range30D rev.Revenue
Current Q-$0.20-$0.20–-$0.20-8.1%$0.00
Next Q-$0.21-$0.21–-$0.21-20.0%$0.00
Current FY-$0.67-$0.67–-$0.67-21.8%$0.00
Next FY-$0.43-$0.43–-$0.43+12.2%$9.5M

Short side

FINRA· Sep 30, 2026
2,657,727
shares short
+18.1%
vs prior settlement
7.0
days to cover
≈9.6%
of shares outstanding
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Oct 21, 2026 SEC
INmune Bio filed an 8-K announcing two key Ebstrocel (CORDStrom) milestones: submission of a pre-MAA package to the UK…
8-K — Impact 7/10
Sep 16, 2026 SEC
James Sapirstein filed a Form 3 initial statement of beneficial ownership with the SEC, reporting no securities…
3 — Impact 2/10
Sep 15, 2026 Insider
SAPIRSTEIN JAMES was granted 100,000 shares
Director
Sep 15, 2026 Insider
Clark Ronnie Duane was granted 100,000 shares
Director
Aug 26, 2026 Announcement
INmune Bio Advances Ebstrocel™ Toward European Marketing Authorization with EMA Regulatory Filings
Orphan Drug Designation application and pre-MAA Scientific Advice package submitted for Ebstrocel™ i
Jul 9, 2026 Press
INmune Bio announced new Phase 2 imaging data for XPro1595 in early Alzheimer's disease, showing statistically…
Impact 5/10
Jul 2, 2026 Insider
Juda Scott acquired via exercise 14,801 shares
Director @ $0.1250 ($1.9K)
Jul 1, 2026 SEC
Inmune Bio entered into warrant inducement agreements with holders of its April 2024 warrants. Holders exercised 50%…
8-K — Impact 5/10
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Upcoming
Nov 4, 2026
Earnings date
INMB Q3 2026 Earnings Scheduled — 2026-11-04
Recent
Aug 26, 2026
Announcement
INmune Bio Advances Ebstrocel™ Toward European Marketing Authorization with EMA Regulatory Filings
Orphan Drug Designation application and pre-MAA Scientific Advice package submitted for Ebstrocel™ in RDEB Filings support a planned EU MAA in Q1…
Aug 6, 2026
Earnings
INmune Bio Inc. Announces Second Quarter 2026 Results and Highlights Regulatory, Manufacturing and Clinical Progress
Company to Host Conference Call Today, August 6th, at 4:30pm ET Company to Host Conference Call Today, August 6th, at 4:30pm ET
Aug 6, 2026
Earnings date
INMB Q2 2026 Earnings Scheduled — 2026-08-06
Aug 5, 2026
Earnings date
INMB Q2 2026 Earnings Scheduled — 2026-08-05
Jul 30, 2026
Press release
INmune Bio Establishes Scientific Advisory Board to Support Late-Stage Development and Expansion of CORDStrom™ Platform
Global Experts in MSC Clinical Translation to Advise Ebstrocel™ Regulatory and Clinical Development and Guide Expansion of CORDStrom Product…

SecBot reports

9 filings · 3 press releases · 3 bullish · 1 bearish · 1 mixed · 4 neutral
All INMB filing & press-release reports (12)